Lampl C et al. (2006) A prospective, open-label, long-term study of the efficacy and tolerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 26: 1203–1208
Drugs currently used for treating chronic tension-type headache only reduce headache frequency by about a third and are associated with side effects. Topiramate, an antiepileptic drug with potential mechanisms of action including sodium channel blockade, inhibition of glutamate receptors, and enhancement of γ-aminobutyric acid (GABA)A receptors, has proven efficacy and tolerability in migraine. In a prospective open-label study, Lampl and co-workers have shown this drug to have promise in the prophlyaxis of chronic tension-type headache.
Of the 51 patients enrolled, 46 completed 24 weeks of treatment with topiramate (titrated from 25 mg daily at study start to 100 mg daily by week 4 of treatment). The frequency of headache declined significantly at weeks 13–24 compared with baseline (12.58 ± 6.28 days vs 23.50 ± 5.32 days; P <0.0001), with 73% of patients experiencing a 50% reduction in headache frequency. The frequency of severe headaches also decreased significantly (P <0.0001). On the visual analog scale, average headache intensity dropped from 6.13 to 2.07 (P <0.0001). Mood, sleep, quality of life and Beck Depression Inventory II score also all improved significantly during the study period (P <0.0001 for all). Patients experienced few side effects (none of which were severe) and lost a mean 2.14 kg in weight between baseline and week 24 (P <0.0001), overcoming the problem of weight gain seen with some other prophylactic therapies.
Topiramate would thus seem to be highly effective in preventing chronic tension-type headache, with a more-favorable side effect profile than other available treatments. These preliminary results, however, require further validation.
Rights and permissions
About this article
Cite this article
Topiramate has high efficacy and tolerability in treating chronic tension-type headache. Nat Rev Neurol 2, 641 (2006). https://doi.org/10.1038/ncpneuro0331
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0331